Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.
2.

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR.

Science. 2010 Aug 13;329(5993):856-61. doi: 10.1126/science.1187659. Epub 2010 Jul 8.

3.

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.

Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L.

J Virol. 2009 Sep;83(17):8925-37. doi: 10.1128/JVI.00758-09. Epub 2009 Jun 24.

4.

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site.

Dey B, Svehla K, Xu L, Wycuff D, Zhou T, Voss G, Phogat A, Chakrabarti BK, Li Y, Shaw G, Kwong PD, Nabel GJ, Mascola JR, Wyatt RT.

PLoS Pathog. 2009 May;5(5):e1000445. doi: 10.1371/journal.ppat.1000445. Epub 2009 May 29.

5.

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.

Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R.

J Virol. 2009 Jan;83(2):1045-59. doi: 10.1128/JVI.01992-08. Epub 2008 Nov 12.

6.

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR.

J Virol. 2008 Dec;82(23):11651-68. doi: 10.1128/JVI.01762-08. Epub 2008 Sep 24.

7.

Role of phosphatidylinositol-4-phosphate 5' kinase (ppk-1) in ovulation of Caenorhabditis elegans.

Xu X, Guo H, Wycuff DL, Lee M.

Exp Cell Res. 2007 Jul 1;313(11):2465-75. Epub 2007 Mar 24.

8.

Identification of direct serum-response factor gene targets during Me2SO-induced P19 cardiac cell differentiation.

Zhang SX, Garcia-Gras E, Wycuff DR, Marriot SJ, Kadeer N, Yu W, Olson EN, Garry DJ, Parmacek MS, Schwartz RJ.

J Biol Chem. 2005 May 13;280(19):19115-26. Epub 2005 Jan 28.

9.

The HTLV-I Tax oncoprotein: hyper-tasking at the molecular level.

Wycuff DR, Marriott SJ.

Front Biosci. 2005 Jan 1;10:620-42. Print 2005 Jan 1. Review.

PMID:
15569604
10.

Identification of a functional serum response element in the HTLV-I LTR.

Wycuff DR, Yanites HL, Marriott SJ.

Virology. 2004 Jul 1;324(2):540-53.

11.
12.

Plasticity of quaternary structure: twenty-two ways to form a LacI dimer.

Swint-Kruse L, Elam CR, Lin JW, Wycuff DR, Shive Matthews K.

Protein Sci. 2001 Feb;10(2):262-76.

13.

Identification of an initiator-like element within the HTLV-I promoter.

Wycuff DR, Goff MD, Marriott SJ.

Virology. 2001 Feb 1;280(1):72-9.

14.

Generation of an AraC-araBAD promoter-regulated T7 expression system.

Wycuff DR, Matthews KS.

Anal Biochem. 2000 Jan 1;277(1):67-73.

PMID:
10610690

Supplemental Content

Loading ...
Support Center